BNTC·Nasdaq·US
Benitec Biopharma
Benitec Biopharma is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary DNA-directed RNA interference platform. The company is advancing ddRNAi-based therapeutics for chronic and life-threatening diseases, including programs for OPMD and chronic hepatitis B.
Recent Activity
Updated Oct 31, 2026
–Benitec Biopharma announced positive interim Phase 1b/2a results for high dose BB-301 and continued durable improvements for low dose BB-301.
–Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic patients with Oculopharyngeal Muscular Dystrophy.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.